These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 29084469)

  • 21. Comparing the pharmacokinetics of extended-release tacrolimus (LCP-TAC) to immediate-release formulations in kidney transplant patients.
    Tan T; Bunnapradist S
    Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1175-1186. PubMed ID: 34459696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tacrolimus Concentrations Measured in Excreted Bile in Liver Transplant Recipients: The STABILE Study.
    Rayar M; Tron C; Locher C; Chebaro A; Beaurepaire JM; Blondeau M; Cusumano C; Bardou-Jacquet E; Houssel-Debry P; Camus C; Petitcollin A; Verdier MC; Lakéhal M; Desfourneaux V; Sulpice L; Meunier B; Bellissant E; Boudjema K; Lemaitre F
    Clin Ther; 2018 Dec; 40(12):2088-2098. PubMed ID: 30467013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients.
    Gustavsen MT; Midtvedt K; Robertsen I; Woillard JB; Debord J; Klaasen RA; Vethe NT; Bergan S; Åsberg A
    Clin Transl Sci; 2020 Nov; 13(6):1327-1335. PubMed ID: 32652886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure.
    Saint-Marcoux F; Woillard JB; Jurado C; Marquet P
    Ther Drug Monit; 2013 Jun; 35(3):322-7. PubMed ID: 23666572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.
    Monchaud C; Marquet P
    Clin Pharmacokinet; 2009; 48(7):419-62. PubMed ID: 19691367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†).
    Bouamar R; Shuker N; Hesselink DA; Weimar W; Ekberg H; Kaplan B; Bernasconi C; van Gelder T
    Am J Transplant; 2013 May; 13(5):1253-61. PubMed ID: 23480233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients.
    Lemaitre F; Antignac M; Fernandez C
    Clin Biochem; 2013 Oct; 46(15):1538-41. PubMed ID: 23454394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
    Meçule A; Tinti F; Poli L; Bachetoni A; Umbro I; Nofroni I; Lai Q; Pretagostini R; Berloco PB; Mitterhofer AP
    Transplant Proc; 2011 May; 43(4):1024-7. PubMed ID: 21620042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry.
    Vafadari R; Hesselink DA; Cadogan MM; Weimar W; Baan CC
    Transplantation; 2012 Jun; 93(12):1245-51. PubMed ID: 22643331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies.
    Noll BD; Coller JK; Somogyi AA; Morris RG; Russ GR; Hesselink DA; Van Gelder T; Sallustio BC
    Ther Drug Monit; 2013 Oct; 35(5):617-23. PubMed ID: 23921430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus.
    Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Fernandes FB; Casarini DE; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2009 Feb; 23(1):137-45. PubMed ID: 19267777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients.
    Ferraresso M; Tirelli A; Ghio L; Grillo P; Martina V; Torresani E; Edefonti A
    Pediatr Transplant; 2007 May; 11(3):296-300. PubMed ID: 17430486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation.
    Imanishi Y; Matsui K; Ishida K; Ito S; Matsuura K; Deguchi T; Itoh Y
    Arzneimittelforschung; 2011; 61(3):191-6. PubMed ID: 21528645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Ther Drug Monit; 2019 Aug; 41(4):528-532. PubMed ID: 31259882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tacrolimus in adult hematopoietic stem cell transplantation.
    Gao Y; Ma J
    Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):803-811. PubMed ID: 31595800
    [No Abstract]   [Full Text] [Related]  

  • 37. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure.
    Shuker N; Cadogan M; van Gelder T; Roodnat JI; Kho MM; Weimar W; Hesselink DA
    Ther Drug Monit; 2015 Apr; 37(2):262-9. PubMed ID: 25265255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion to Once-Daily Tacrolimus Results in Increased p38MAPK Phosphorylation in T Lymphocytes of Kidney Transplant Recipients.
    Kannegieter NM; Shuker N; Vafadari R; Weimar W; Hesselink DA; Baan CC
    Ther Drug Monit; 2016 Apr; 38(2):280-4. PubMed ID: 26606072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes.
    Tavira B; Coto E; Díaz-Corte C; Ortega F; Arias M; Torres A; Díaz JM; Selgas R; López-Larrea C; Campistol JM; Alvarez V;
    Clin Chem Lab Med; 2011 May; 49(5):825-33. PubMed ID: 21480817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial.
    Kannegieter NM; Hesselink DA; Dieterich M; de Graav GN; Kraaijeveld R; Baan CC
    Sci Rep; 2017 Nov; 7(1):15135. PubMed ID: 29123208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.